- Home
- EU vs PCRX Comparison
EU vs PCRX Comparison
Compare EU & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EU
- PCRX
- Stock Information
- Founded
- EU 2009
- PCRX 2006
- Country
- EU United States
- PCRX United States
- Employees
- EU N/A
- PCRX N/A
- Industry
- EU Other Metals and Minerals
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- EU Basic Materials
- PCRX Health Care
- Exchange
- EU Nasdaq
- PCRX Nasdaq
- Market Cap
- EU N/A
- PCRX 1.2B
- IPO Year
- EU N/A
- PCRX 2011
- Fundamental
- Price
- EU $2.93
- PCRX $23.22
- Analyst Decision
- EU Strong Buy
- PCRX Buy
- Analyst Count
- EU 1
- PCRX 8
- Target Price
- EU $2.75
- PCRX $28.38
- AVG Volume (30 Days)
- EU 3.7M
- PCRX 569.8K
- Earning Date
- EU 08-13-2025
- PCRX 07-29-2025
- Dividend Yield
- EU N/A
- PCRX N/A
- EPS Growth
- EU N/A
- PCRX N/A
- EPS
- EU N/A
- PCRX N/A
- Revenue
- EU $46,179,000.00
- PCRX $702,772,000.00
- Revenue This Year
- EU $27.46
- PCRX $7.54
- Revenue Next Year
- EU $140.12
- PCRX $10.78
- P/E Ratio
- EU N/A
- PCRX N/A
- Revenue Growth
- EU N/A
- PCRX 3.08
- 52 Week Low
- EU $1.01
- PCRX $11.16
- 52 Week High
- EU $4.44
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- EU 71.64
- PCRX 35.42
- Support Level
- EU $2.25
- PCRX $22.82
- Resistance Level
- EU $2.93
- PCRX $24.36
- Average True Range (ATR)
- EU 0.20
- PCRX 0.69
- MACD
- EU 0.04
- PCRX -0.12
- Stochastic Oscillator
- EU 96.81
- PCRX 17.09
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.